Delivery Order SPE2DR25D2206-SPE2DR26F9LT2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,248.66 to AmerisourceBergen Drug Corp for BENLYSTA 200 mg/mL auto-injector on December 4, 2025, with completion scheduled for December 26, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded through the federal procurement process. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $6,973.34 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 200 mg/ml Benlysta auto-injector medication on January 9, 2026, with completion targeted for February 2, 2026. The award was made on a non-set-aside, competitive basis and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s substantial Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,497.32 for Benlysta 200 mg/ml auto-injector on November 18, 2025, with an ultimate completion date of December 10, 2025. This is a firm fixed price, non-set-aside contract executed as a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a $27,893.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp for BENLYSTA 200 MG/ML auto-injector on January 15, 2026, with an ultimate completion date of February 6, 2026. This is a non-set-aside contract, awarded competitively to the pharmaceutical distributor's Corporate Office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $55,488.06 for Benlysta 200 mg/ml auto-injectors on September 17, 2025, with an ultimate completion date of October 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp on July 10, 2025, for the supply of Benlysta 200 mg/mL auto-injector units. This competitively awarded, non-set-aside contract carries a ceiling value of $6,165.34 and is scheduled for completion by July 31, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Benlysta (belimumab) is a biologic immunosuppressant used to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,973.34 to AmerisourceBergen Drug Corp for BENLYSTA 200 mg/mL auto-injector on January 14, 2026, with an ultimate completion date of February 5, 2026. This firm fixed-price, competitively awarded contract carries no set-aside designation. The award represents a task order under AmerisourceBergen's parent company, Cencora, Inc.'s large Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at up to...
- The Defense Logistics Agency awarded a delivery order valued at $3,486.67 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/ml auto-injector on January 20, 2026, with an ultimate completion date of February 10, 2026. This non-set-aside, firm fixed-price delivery order was issued under AmerisourceBergen's parent company Cencora, Inc.'s substantial Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999.9 million through December 2031. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $6,973.34 to AmerisourceBergen Drug Corp for BENLYSTA 200 mg/mL auto-injector on January 16, 2026, with completion scheduled for February 9, 2026. This firm fixed-price, non-set-aside contract is being performed in Conshohocken, Pennsylvania, where the awardee maintains its corporate headquarters. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor providing critical...
- The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 11, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody biologic therapy indicated for treating systemic...
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9LT2Delivery Order
The Defense Logistics Agency awarded a $3,486.67 firm fixed-price delivery order to AmerisourceBergen Drug Corp for BENLYSTA 200 mg/ml auto-injector on January 16, 2026, with an ultimate completion date of February 9, 2026. This competitively awarded, non-set-aside contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 and extending through December 31, 2031, which serves as the primary vehicle for delivering comprehensive pharmaceutical products and medical supplies to support military healthcare programs globally. BENLYSTA (belimumab) is a biologic immunosuppressant used to treat systemic lupus erythematosus and lupus nephritis, and its procurement through the DLA supply chain reflects the Defense Health Agency's medical support requirements for service members and military beneficiaries. AmerisourceBergen's extensive federal contract portfolio demonstrates its critical role as a pharmaceutical distributor within the military healthcare ecosystem, with the company supplying a diverse range of specialty medications, brand-name and generic drugs, and medical devices across multiple therapeutic domains to military treatment facilities and veteran healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 1/15/26 |